January 2023 in “Indian Dermatology Online Journal” This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.
17 citations
,
October 2005 in “Journal of Biological Chemistry” This study found that Hirosaki hairless rats experience transient activation of STAT5A in the mammary glands during early lactation, involving O-GlcNAc modification rather than Tyr-phosphorylation.
The researchers reported that PEG-FGF2 conjugates, particularly Compound 6, significantly enhanced stability, proliferation, migration, and wound healing activity compared to native FGF2, despite some reduction in bioactivity near crucial binding domains.
24 citations
,
July 2021 in “Pharmaceutics” This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
94 citations
,
July 2003 in “Journal of biological chemistry/The Journal of biological chemistry” This study found that continuous expression of epidermal growth factor in transgenic mice prevented hair follicles from entering the catagen phase, implicating EGF as a crucial regulator in hair cycle progression.
27 citations
,
March 2006 in “Molecular Plant Pathology” This article reviews the molecular events in legume-rhizobia symbiosis, focusing on gene regulation, symbiotic pathways, and infection processes, but does not present new experimental findings.
15 citations
,
February 2021 in “Frontiers in immunology” This review discusses leptin's regulatory roles in the progression of various dermatological diseases and reports no new clinical results, highlighting a complex relationship still under investigation.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.
2 citations
,
April 2024 in “Journal of Dermatological Science” This study suggests that the MLKL-targeting inhibitor Necrosulfonamide promotes hair growth and counteracts DHT inhibition by activating Wnt signaling in hair follicle cells, revealing potential avenues for anti-alopecia drug development.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.
January 2025 in “International Journal of Pharmaceutics” In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.
6 citations
,
June 2012 in “PloS one” This study identified a novel SCF mRNA splice variant in white merino sheep skin, which may play a role in hair follicle melanogenesis.
3 citations
,
September 2024 in “International Journal of Molecular Sciences” This review examines how mathematical modeling of the MAPK pathway, enhanced by single-cell proteomic data, improves understanding of regulatory mechanisms, predicts system behavior, and guides experimental research, emphasizing recent developments in modeling and inference.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
September 2025 in “International Journal of Molecular Sciences” This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.
February 2023 in “Pharmaceutics” This study found that oral administration of 7, 8–dihydroxyflavone in guinea pigs improved recovery from gentamicin-induced vestibular damage, suggesting potential therapeutic use for vestibular dysfunction in humans.
78 citations
,
August 2017 in “Endocrine Reviews” This review discusses the free hormone hypothesis for measuring "free" testosterone and critiques its theoretical basis and clinical application, noting it lacks critical empirical testing and has inconsistent utility in assessing androgen status.
44 citations
,
May 2023 in “MedComm” This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.
41 citations
,
October 2001 in “Experimental Dermatology” This review discusses the molecular and functional aspects of the nude gene in skin biology, providing insights into its role and evolutionary development, but reports no new results.
37 citations
,
April 2018 in “Journal of Allergy and Clinical Immunology” This study found that a novel IKZF1 mutation, p.L188V, is linked to juvenile-onset systemic lupus erythematosus and alters B-cell activation by disrupting normal DNA binding.
15 citations
,
December 2018 in “International journal of environmental research and public health/International journal of environmental research and public health” This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.
14 citations
,
November 2024 in “Pharmaceuticals” This study found that using spanlastics, a nano, surfactant-based drug delivery system, improved the bioavailability, drug release characteristics, and pharmacokinetic behavior of famotidine, a poorly soluble drug, by enhancing its dissolution and membrane permeation.
9 citations
,
March 2019 in “Molecular & cellular proteomics” In this study, around 1% of proteins in skin fibroblasts significantly changed in response to reductive stress, affecting collagens and MAPK signaling pathways.
8 citations
,
November 2025 in “Journal of Translational Medicine” This review highlights challenges in developing drugs targeting the Wnt/β-Catenin signaling pathway for cancer due to its complexity and essential roles in normal tissue. It explores targeted protein degradation technology as a promising strategy to overcome these challenges, suggesting potential new avenues for drug development.
7 citations
,
January 2023 in “Frontiers in Cell and Developmental Biology” This review provides a comprehensive overview of apoptosis-related molecules in head development, highlighting caspases' roles and associated abnormalities in tissues like the brain, sensory organs, skin, and bones, without reporting new results.
6 citations
,
February 2023 in “Cosmetics” This study found that hexane extracts of Nostoc verrucosum significantly inhibited melanin synthesis in melanoma cells and demonstrated antioxidant activity, suggesting potential use in developing cosmetic and functional food products.
5 citations
,
March 2025 in “Pediatric Dermatology” This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.
5 citations
,
December 2021 in “Frontiers in Cell and Developmental Biology” This review outlines how peptidyl arginine deiminases (PADIs) and protein citrullination are involved in hair follicle regeneration and inflammatory alopecia, but presents no new clinical findings.
3 citations
,
August 2024 in “Frontiers in Oncology” This review explores molecular targets for head and neck squamous cell carcinoma and discusses potential advancements in radiopharmaceuticals for targeted radionuclide therapy, reporting no new clinical results.